Skip to main content

and
  1. Article

    Open Access

    Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma

    The present randomised phase II study was an effort to evaluate single-agent gemcitabine as a first-line systemic treatment of Asian patients with unresectable hepatocellular carcinoma (HCC). Gemcitabine was g...

    Z Guan, Y Wang, S Maoleekoonpairoj, Z Chen, W S Kim in British Journal of Cancer (2003)